Peptide Guide
Next Generation Weight Loss Drugs: What Is Coming After GLP-1
Executive Brief
The weight loss drug pipeline is packed with next-generation compounds that aim to surpass semaglutide and tirzepatide. Retatrutide, CagriSema, survodutide, Mazdutide, orforglipron, and amycretin are all in late-stage development. This guide covers what each drug does, how it differs from current options, and when you might be able to access them. ---
Retatrutide
Survodutide
Where the pipeline came from
The success of semaglutide and tirzepatide triggered an arms race in obesity drug development. After tirzepatide proved that hitting two receptors (GLP-1 and GIP) was better than one, pharmaceutical companies started asking: what if we hit three receptors? What if we added another mechanism entirely? The result is a pipeline with more active obesity drug candidates than at any point in history. Over 100 anti-obesity medications are in clinical development as of 2026. The most advanced candidates are in phase 3 trials or have completed them. The strategies fall into a few categories. Multi-receptor agonists hit GLP-1 plus GIP plus glucagon, or GLP-1 plus glucagon. Oral formulations remove the injection barrier. Combination therapies stack two drugs with different mechanisms. Novel targets explore pathways like amylin, myostatin, and leptin sensitization. This is not a speculative future. Several of these drugs will likely be approved within the next 1 to 3 years. Some may be available through compounding pharmacies sooner, depending on regulatory timelines.
How the pipeline works
Each next-generation drug has a distinct mechanism. Here is what each one targets. Retatrutide is a triple agonist hitting GLP-1, GIP, and glucagon receptors. The GLP-1 component suppresses appetite. The GIP component enhances metabolic effects and may reduce nausea. The glucagon component increases energy expenditure and fat oxidation. It is the first triple-receptor agonist in obesity trials, and the early data is the most impressive of any drug in the pipeline. CagriSema is a combination of cagrilintide (a long-acting amylin analog) and semaglutide. Amylin is a hormone co-secreted with insulin from the pancreas. It slows gastric emptying, promotes satiety, and reduces post-meal glucagon. Cagrilintide adds the amylin mechanism on top of GLP-1, producing more weight loss than semaglutide alone. Survodutide is a dual GLP-1/glucagon receptor agonist. It combines appetite suppression with increased energy expenditure. The glucagon component may help maintain metabolic rate during caloric restriction, which is a common problem with GLP-1 only drugs. Mazdutide is another dual GLP-1/glucagon agonist, developed by Innovent Biologics. It has shown strong weight loss results in Chinese populations and is further along in development in China and parts of Asia. Orforglipron is an oral GLP-1 agonist. Unlike semaglutide's oral formulation (Rybelsus), which requires fasting and a specific absorption enhancer, orforglipron is a small molecule that is absorbed without these restrictions. This makes daily oral dosing much more practical. The weight loss is comparable to injectable semaglutide. Amycretin is a dual GLP-1/amylin receptor agonist. It targets both the GLP-1 pathway and the amylin pathway in a single molecule, unlike CagriSema which combines two separate drugs. The amylin component adds satiety signaling on top of GLP-1 appetite suppression.
Triple and quadruple agonists
What it actually does
Here are the weight loss results from the latest clinical trial data. Retatrutide: Phase 2 data showed 24.2 percent body weight loss at 48 weeks with the highest dose (12mg). Some participants exceeded 30 percent weight loss. Phase 3 trials are ongoing. If the phase 3 data holds, retatrutide will produce the most weight loss of any drug ever tested. CagriSema: Phase 2 data showed 15.6 percent weight loss at 32 weeks with the combination, compared to 5.1 percent with cagrilintide alone and 10.4 percent with semaglutide alone. Phase 3 trials are testing higher doses and longer duration. Weight loss of 20 percent or more is expected. Survodutide: Phase 2 data showed 14.9 percent weight loss at 23 weeks, which is impressive for such a short trial. Weight loss was still accelerating at the end of the study, suggesting higher results over longer periods. Phase 3 trials are underway. Mazdutide: Phase 2 data showed 11.3 percent weight loss at 24 weeks in Chinese participants. Phase 3 data is expected soon. It may produce results similar to semaglutide, around 15 percent or slightly higher. Orforglipron: Phase 2 data showed 14.7 percent weight loss at 36 weeks. The oral dosing is a major advantage for people who do not want injections. Phase 3 trials are ongoing. If approved, it would be the first highly effective oral GLP-1 agonist without the food restrictions of Rybelsus. Amycretin: Earlier stage data. Phase 2 trials are ongoing. The dual GLP-1/amylin mechanism is promising, but weight loss numbers from larger trials are not yet available.
How it feels
No one outside of clinical trials has used retatrutide yet. But based on the mechanism, we can anticipate what these drugs will feel like. Triple agonists like retatrutide will likely have a similar appetite suppression profile to tirzepatide but with greater metabolic effects. The glucagon component may cause more initial side effects since glucagon raises blood sugar acutely before the GLP-1 and GIP components compensate. Trial participants reported nausea and diarrhea during dose escalation, similar to existing GLP-1 drugs. Oral drugs like orforglipron will change the user experience entirely. No needles, no reconstitution, no refrigeration. Just take a pill once daily. The convenience factor alone will drive adoption. Side effects are expected to mirror injectable GLP-1 drugs. A user on r/Mounjaro who participated in a clinical trial for a next-gen compound shared: “Cannot say which drug, but it is in the pipeline. Appetite suppression was stronger than what I experienced on Mounjaro. Lost about 8 percent body weight in 12 weeks. Side effects were manageable, mostly nausea in the first month. Excited for this to come to market.“
Benefits you will notice (from pipeline drugs, once available)
- Greater weight loss potential, possibly 25 to 30 percent body weight with triple agonists
- Oral options that eliminate the need for injections
- Better metabolic outcomes beyond weight loss, including improved blood sugar and liver fat reduction
- Potentially fewer side effects through smarter receptor targeting
- Options for people who did not respond well to current GLP-1 drugs
Peptides that pair well with pipeline drugs
Once approved, the same stacking principles will apply. Pipeline GLP-1/GIP/glucagon drugs will pair well with AOD-9604 for stubborn fat, MOTS-c for metabolic support, and GH peptides for muscle preservation. The core strategy of appetite suppression plus metabolic optimization plus muscle protection remains relevant regardless of which drug handles the appetite suppression. BPC-157 will likely be a useful adjunct for managing GI side effects, as it is with current GLP-1 drugs. The main change will be that fewer people need to stack multiple weight loss peptides, because a single triple agonist may cover appetite suppression, fat oxidation, and metabolic improvement in one molecule.
Frequently Asked Questions
When will retatrutide be available?
Eli Lilly's phase 3 trials are ongoing with expected completion in 2027. FDA approval could come in 2027 or 2028. Compounding pharmacies may begin offering it sooner if the active ingredient becomes available, though this depends on regulatory and patent status.
Will these drugs be expensive?
Initially, yes. GLP-1 drugs launched at over $1,000 per month. Next-generation drugs will likely follow a similar pattern. Prices will drop over time as competition increases, more manufacturers enter the market, and insurance coverage expands. Compounded versions will be cheaper from the start.
Are oral GLP-1 drugs as effective as injections?
Orforglipron data suggests yes, at least for weight loss. The oral formulation produced 14.7 percent weight loss in phase 2 trials, comparable to injectable semaglutide. The key advantage is convenience. The potential disadvantage is that daily dosing requires consistent compliance, whereas weekly injections are more forgiving.
What is the safest next-generation drug?
We do not know yet. Safety data accumulates over years of use, not months of trials. All these drugs share the GLP-1 mechanism, so they will likely share similar side effect profiles: nausea, diarrhea, constipation, and the thyroid warning. The additional receptors (glucagon, amylin) may introduce new side effects that do not appear until larger populations use the drugs.
Should I wait for next-generation drugs or start with what is available now?
If you need to lose weight now, starting with semaglutide or tirzepatide makes sense. You can always switch to a next-generation drug when it becomes available. Waiting for a future drug means waiting for a future that may be 2 to 3 years away. Both semaglutide and tirzepatide produce clinically meaningful weight loss. The best drug is the one you can access and afford today.
Research Disclaimer
All content on this page is provided for informational and research purposes only. Nothing here constitutes medical advice, diagnosis, or treatment recommendation. Always consult a qualified healthcare professional before using any compound.